Kim Soo-Kyung, Kim Se-Hwa, Park Kyung-Sun, Park Seok-Won, Cho Yong-Wook
Department of Internal Medicine, CHA University School of Medicine, Sungnam, Korea.
Endocr J. 2009;56(6):753-8. doi: 10.1507/endocrj.k09e-049. Epub 2009 Jun 9.
The association between subclinical hypothyroidism and cardiovascular disease and the beneficial effect of levothyroxine replacement in subclinical hypothyroidism are still under debate. The present study was designed to determine whether subclinical hypothyroidism is associated with an increase in the intima-media thickness of the common carotid artery (C-IMT) and whether thyroid hormone replacement can reverse this change in the C-IMT. Patients with newly-diagnosed subclinical (n=36) and overt (n=40) hypothyroidism and healthy euthyroid individuals (n=32) participated in this study. All the patients were examined for clinical characteristics, and the serum lipid levels and the C-IMT were measured. Patients with subclinical hypothyroidism had a C-IMT measurement after 18 months of levothyroxine replacement. There were meaningful differences in total cholesterol and LDL-cholesterol levels between patients with subclinical hypothyroidism and euthyroidism. The subjects with subclinical and overt hypothyroidism had a greater C-IMT compared with euthyroid controls (0.66+/- 0.10 and 0.70+/- 0.11 vs. 0.57+/- 0.08 mm, respectively; P < 0.05). After 12 months of euthyroidism, 28 of 36 patients with subclinical hypothyroidism completed the follow-up study. Thyroid hormone replacement significantly decreased the C-IMT (0.67+/- 0.11 to 0.60+/- 0.10 mm; P = 0.021) and improved the lipid profile. Based on multiple regression analysis, the decrement in LDL-cholesterol was independently associated with the regression of the C-IMT. Subclinical hypothyroidism was closely related to an increased C-IMT. Thyroid hormone replacement resulted in regression of the increased C-IMT, which was attributed to the improvement in the lipid profile.
亚临床甲状腺功能减退与心血管疾病之间的关联以及左甲状腺素替代治疗对亚临床甲状腺功能减退的有益作用仍存在争议。本研究旨在确定亚临床甲状腺功能减退是否与颈总动脉内膜中层厚度(C-IMT)增加有关,以及甲状腺激素替代治疗能否逆转C-IMT的这种变化。新诊断的亚临床甲状腺功能减退患者(n = 36)、显性甲状腺功能减退患者(n = 40)和健康的甲状腺功能正常个体(n = 32)参与了本研究。所有患者均接受临床特征检查,并测量血脂水平和C-IMT。亚临床甲状腺功能减退患者在接受左甲状腺素替代治疗18个月后进行C-IMT测量。亚临床甲状腺功能减退患者与甲状腺功能正常患者的总胆固醇和低密度脂蛋白胆固醇水平存在显著差异。与甲状腺功能正常的对照组相比,亚临床和显性甲状腺功能减退患者的C-IMT更大(分别为0.66±0.10和0.70±0.11 vs. 0.57±0.08 mm;P < 0.05)。甲状腺功能正常12个月后,36例亚临床甲状腺功能减退患者中有28例完成了随访研究。甲状腺激素替代治疗显著降低了C-IMT(从0.67±0.11降至0.60±0.10 mm;P = 0.021)并改善了血脂谱。基于多元回归分析,低密度脂蛋白胆固醇的降低与C-IMT的消退独立相关。亚临床甲状腺功能减退与C-IMT增加密切相关。甲状腺激素替代治疗导致增加的C-IMT消退,这归因于血脂谱的改善。